Benzinga··Globe NewswirePathos AI Acquires DeuterOncology to Commercialize Next-Gen MET Inhibitor
Pathos AI acquires majority stake in DeuterOncology to advance DO-2, a MET inhibitor showing 100% tumor shrinkage in Phase 1 with superior safety profile.
AZNTEMPhase 1 clinical trialoncology